Jack A. Khattar - 28 Feb 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
28 Feb 2024
Transactions value $
-$469,057
Form type
4
Filing time
29 Feb 2024, 17:00:51 UTC
Previous filing
26 Feb 2024
Next filing
11 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +35,000 +3.9% $0 932,005 28 Feb 2024 Direct F1
transaction SUPN Common Stock Tax liability -$469,056 -16,788 -1.8% $27.94 915,217 28 Feb 2024 Direct F2
holding SUPN Common Stock 1,022,450 28 Feb 2024 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Options Exercise $0 -35,000 -100% $0* 0 28 Feb 2024 Common Stock 35,000 $0 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.